⌘K
Loading ticker…
As of 2026-08-24, Annovis Bio, Inc. (ANVS) has a 3-month relative strength percentile of 19 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 39. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.7%, relative volume 1.16×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ANVS is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -2.5% / -29.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ANVS appears in 1 ETF as of Apr 2026: DFAS at 0.00% weight, $24K notional.
Held by 3 ETFs · $2M across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Apr 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| DFASDimensional U.S. Small Cap ETF | 0.00% | $24K | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ANVS Jan avg: -10.76% median: -12.57% win: 25% σ: 27.28% n: 4 2022-04-12 → 2026-07-31 | ANVS Feb avg: -20.73% median: -12.04% win: 25% σ: 30.20% n: 4 2022-04-12 → 2026-07-31 | ANVS Mar avg: -1.07% median: -13.36% win: 25% σ: 27.94% n: 4 2022-04-12 → 2026-07-31 | ANVS Apr avg: -18.06% median: -11.66% win: 0% σ: 20.85% n: 5 2022-04-12 → 2026-07-31 | ANVS May avg: 11.99% median: -2.54% win: 40% σ: 27.56% n: 5 2022-04-12 → 2026-07-31 | ANVS Jun avg: 1.95% median: -3.13% win: 40% σ: 14.41% n: 5 2022-04-12 → 2026-07-31 | ANVS Jul avg: 15.89% median: 1.41% win: 60% σ: 28.51% n: 5 2022-04-12 → 2026-07-31 | ANVS Aug avg: -8.43% median: -9.61% win: 25% σ: 6.78% n: 4 2022-04-12 → 2026-07-31 (current) | ANVS Sep avg: -5.12% median: -7.56% win: 25% σ: 17.36% n: 4 2022-04-12 → 2026-07-31 | ANVS Oct avg: -5.54% median: -3.47% win: 50% σ: 19.15% n: 4 2022-04-12 → 2026-07-31 | ANVS Nov avg: 37.67% median: 17.77% win: 75% σ: 73.84% n: 4 2022-04-12 → 2026-07-31 | ANVS Dec avg: 15.75% median: -12.56% win: 25% σ: 71.02% n: 4 2022-04-12 → 2026-07-31 |